Abstracts tagged "Drug toxicity"

Abstract Number: 1089 • ACR Convergence 2025
Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Inflammatory arthritis (IA)- and polymyalgia rheumatica (PMR)-like syndromes occur in about 6% of patients receiving an immune checkpoint inhibitor (ICI) and can worsen quality…
Abstract Number: 1913 • ACR Convergence 2025
Do We Screen For and Do We Miss Antimalarial-Induced Cardiomyopathy (AMIC)? Risk Profiles according to Hydroxychloroquine Exposure Duration
Youngmin Kim¹, Robert Padera², Brittany Weber³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, DEDHAM, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for autoimmune diseases but carries a risk of antimalarial-induced cardiomyopathy (AMIC) that increases with long-term use and is often…
Abstract Number: 1088 • ACR Convergence 2025
Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: The broad use of immune checkpoint inhibitors (ICIs) in oncology has led to the emergence of ICI-induced inflammatory arthritis (ICI-IA). The aim of this…
Abstract Number: 1886 • ACR Convergence 2025
Thirty Percent of Older Adults with Rheumatic Disease Receive High-Risk Medication
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: High-risk medications (HRMs) may increase the risk of adverse events such as falls and fractures, hospitalizations, hospital length of stay, and death in older…
Abstract Number: 1048 • ACR Convergence 2025
Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
Malika Ibrahim¹, Samuel Good², Victor Tran³, David Chetrit⁴, Michael McClean⁵, Myung Shin Sim⁶, Hannah Kang¹, Jennifer Barton⁷, Meika Fang⁸, Angelo Gaffo⁹, fadi Hage¹⁰, cynthia Jackevicius⁵, Michael Pillinger¹¹, gabriela Schmajuk¹², Jasvinder Singh¹³, Alberta Warner¹⁴, Neal Yaun¹⁵ and John FitzGerald¹⁶, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ³David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Costa Mesa, CA, ⁴Carolina Health Specialists, Myrtle Beach, SC, ⁵Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, ⁶West LA VA Medical Center, Los Angeles, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁹Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ¹⁰VA Birmingham health care, Birmingham, AL, ¹¹New York University Grossman School of Medicine, New York,, NY, ¹²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ¹³Baylor College of Medicine, Houston, TX, ¹⁴VA Greater Los Angeles/UCLA, Los Angeles, ¹⁵UCSF / SFVA, San Francisco, ¹⁶UCLA, Los Angeles, CA
Background/Purpose: Hydroxychloroquine (HCQ) is widely used for rheumatic diseases, but data on its cardiac safety, particularly QTc prolongation, remains limited. Concerns about HCQ inducing QTc…
Abstract Number: 1735 • ACR Convergence 2025
Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation
Elise Herardot¹, Nadine Soliman¹, Audrey Pigenet¹, Ilana Slotine¹, Anni Herranan², Samia Bahieddine¹, Jean-Baptiste Fini², Olivier Tabary¹, Adeline Cambon³, Xavier HOUARD⁴, Francis BERENBAUM⁵, SELLAM JEREMIE⁶ and Alice Courties⁷, ¹Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, Paris, France, ²UMR ⁷²²¹, Phyma, CNRS–Muséum National d’Histoire Naturelle, Sorbonne Université, ⁷⁵⁰⁰⁵ Paris, France, Paris, France, ³Department of Orthopedic, Trauma and Hand Surgery, Hôpital Saint-Antoine, Sorbonne University, ¹⁸⁴ Rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France, ⁴Centre de Recherche Saint-Antoine, UMR_S⁹³⁸ INSERM /Sorbonne Université, Paris, France, PARIS, France, ⁵Sorbonne University/Inserm/AP-HP/⁴Moving Biotech, Paris, France, ⁶Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France, ⁷Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹², Paris, France / Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France, Paris, France
Background/Purpose: Osteoarthritis (OA) affects over 590 million individuals globally. Epidemiological data suggest that exposure to environmental pollutants, particularly endocrine-disrupting chemicals (EDCs) such as phthalates, PFAS,…
Abstract Number: 0670 • ACR Convergence 2025
Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis
Zahraa Qamhieh¹, Dalia Sriwi¹, Callie Saric², Tripti Singh³, Christie Bartels⁴ and Shivani Garg⁵, ¹University of Wisconsin, Madison, Department of Medicine, Madison, WI, ²University of Wisconsin, Madison, School of Medicine and Public Health, Madison, WI, ³University of Wisconsin, Madison, Department of Nephrology, Madison, WI, ⁴University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Clinical response to Mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug monitoring (TDM) of MPA could help improve treatment efficacy. Our objective in…
Abstract Number: 1731 • ACR Convergence 2025
A Post-Marketing Analysis of Autoimmune Toxicities Following Chimeric Antigen Receptor T-Cell Therapy Using the FDA Adverse Event Reporting System
Malvika Gupta¹, Christopher Graham² and Supriya Gupta³, ¹Mayo Clinic, Rochester MN, Rochester, MN, ²University of Minnesota, Minneapoils, MN, ³University of Minnesota, Minneapolis, MN
Background/Purpose: Chimeric Antigen Receptor (CAR-T) therapy has transformed the management of hematologic cancers, with multiple products approved by the U.S. Food and Drug Administration (FDA).…
Abstract Number: 0669 • ACR Convergence 2025
Clinical and Laboratory Factors Associated With Biopsy-Confirmed Antimalarial-Induced Cardiomyopathy
Youngmin Kim¹, Norioscar Cabello², Robert Padera², Brittany Weber³ and Karen H. Costenbader⁴, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, ³Brigham and Women's Hospital, DEDHAM, MA, ⁴Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is widely prescribed in rheumatology, particularly for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Though generally safe, HCQ can cause rare…
Abstract Number: 1718 • ACR Convergence 2025
Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
Kevin Sheng-Kai Ma¹, Dominique Feterman Jimenez², You Wu³, Jenna Thomason³, Jean Liew⁴ and Namrata Singh⁵, ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²University of Washington, Seattle, ³University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their safety profile in patients with pre-existing autoimmune diseases, such as systemic lupus erythematosus (SLE),…
Abstract Number: 0655 • ACR Convergence 2025
Blood pressure remains elevated in patients initiating voclosporin with low baseline blood pressure: evidence from patients in routine clinical care
Eric Roberts¹, gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: Hypertension was a common adverse event in RCTs testing voclosporin, an oral calcineurin inhibitor approved in 2021 to treat lupus nephritis (LN). In these…
Abstract Number: 1604 • ACR Convergence 2025
Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study
Lucas Khellaf¹, Raphaele Seror², caterina ricordi³, stephanie chhun⁴, audes gleizes⁴, hervé lobbes⁵, clara pouchelon⁶, marie Charlotte Besse⁷, Jean-Emmanuel Kahn⁸, sabine revuz⁹, Marina Cumin¹⁰, Dimitri Titeca-Beauport¹¹, Matthias Papo⁶, Philippe Rémy⁶, marie Desprets¹², florian garo¹³, Charles Ronsin¹⁴, Salima Hacein-Bey-Abina⁶, Amélie Servettaz¹⁵, Cacoub Patrice¹⁶, Xavier Puéchal¹⁷ and Benjamin Terrier¹⁸, ¹AP-HP, Paris, ²Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ³Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ⁴APHP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, ⁶APHP, Paris, France, ⁷CHU Tours, Tours, France, ⁸Ambroise Paré hospital, Boulogne, France, ⁹CHU de la Réunion, Réunion, France, ¹⁰Centre hospitalier de Libourne, Libourne, France, ¹¹CHU Amiens, Amiens, France, ¹²CH Chôlet, Cholet, France, ¹³CHU Nîmes, Nîmes, France, ¹⁴CHU Nantes, Nantes, France, ¹⁵Internal Medicine, CHU Reims, Reims, France, ¹⁶Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹⁷Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ¹⁸Cochin Hospital, Paris, France
Background/Purpose: Small vessel vasculitis mainly includes ANCA-associated vasculitis (AAV) and cryoglobulinemic vasculitis (CV), leading to significant organ damage. Rituximab (RTX), an anti-CD20 monoclonal antibody, has…
Abstract Number: 0352 • ACR Convergence 2025
Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures
Marshall Weber¹, William Obremskey², Jared Huling³, Nitya Shah³, Emily Budde⁴, Zhiping Huo⁴, Reside Jacob⁴, Brinda Basida¹, Colton Hoffer¹, Binni Makkar⁵ and Laura Carbone¹, ¹Augusta University, Augusta, GA, ²Vanderbilt University, Nashville, TN, ³University of Minnesota School of Public Health, Minneapolis, MN, ⁴Center of Innovation for Complex Chronic Healthcare, Washington DC, DC, ⁵University of Kentucky, Lexington, KY
Background/Purpose: Atypical femoral fractures (AFFs) are a rare complication of bisphosphonate use and a major reason that drug holidays are recommended following bisphosphonate use. However,…
Abstract Number: 1593 • ACR Convergence 2025
Comparison of rituximab induction and maintenance regimens in ANCA-associated vasculitis: PK/PD modelling approach in real-world patients
Blaise Pasquiers¹, Benoit Blanchet², Xavier Puéchal³, Xavier Declèves¹, Pascal Cohen⁴, Claire Goulvestre¹, Marion Casadevall¹, Ines Benhabiles¹, Michel Vidal¹, David Ternant¹, Benjamin Terrier⁵ and Alicja Puszkiel⁶, ¹Hopital Cochin, Paris, France, ²National Referral Centre for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, Paris, France, ³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Cochin Hospital, Paris, France, ⁶Cochin Hospital, Paris
Background/Purpose: For the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), rituximab (RTX) may be given as a 4-dose regimen (375 mg/m2 weekly for 4…
Abstract Number: 0230 • ACR Convergence 2025
An Epic journey – Therapeutic Drug Monitoring at an Academic Center
Puja Khanna¹ and Michael Rice², ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Gastroenterology, University of Michigan, Ann Arbor, MI
Background/Purpose: Non-oncologic use of immunomodulatory agents is increasing. These drugs have a narrow, patient-specific therapeutic index, making therapeutic drug monitoring essential for safe prescribing. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].